This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite
by Zacks Equity Research
PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
by Zacks Equity Research
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
by Zacks Equity Research
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
by Zacks Equity Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
Bruker (BRKR) to Advance 4D Proteomics With Latest Launch
by Zacks Equity Research
Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data
by Zacks Equity Research
Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.
Intercept (ICPT) Announces Delay in Meeting With the FDA
by Zacks Equity Research
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract
by Zacks Equity Research
Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
by Zacks Equity Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
by Zacks Equity Research
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails
by Zacks Equity Research
Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.
Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.
Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
by Zacks Equity Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.
Pfizer (PFE) Leads as US Plans Kids' COVID Vaccination in June
by Zacks Equity Research
The FDA accepts the EUA request from Pfizer (PFE) for its COVID-19 vaccine for use in kids below 5 years of age. The U.S. government plans to start vaccinating these kids in June, following an FDA panel advisory.
Why Is Incyte (INCY) Down 7.1% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEOGEN (NEOG) Launches Insecticide for Poultry Producers
by Zacks Equity Research
NEOGEN's (NEOG) insect control solution for poultry producers is the latest addition to the company's Prozap product line.
Insulet (PODD) to Expand Base in Malaysia With New Facility
by Zacks Equity Research
The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.